Join leading voices from across the biopharmaceutical industry, including Abzena’s Director of Analytics, Fabio Rossi, as they discuss the analytical and bioanalytical challenges shaping the next generation of bioconjugate therapeutics.

As the field expands beyond traditional Antibody-drug conjugates (ADCs) to include increasingly complex modalities, such as antibody-oligonucleotide conjugates (AOCs), bispecific ADCs, and dual-payload constructs, development teams need a more integrated understanding of molecular attributes, product heterogeneity, stability, and behavior in biological systems.

In this SelectScience^® Accelerating Science Forum, these experts will explore how characterization and bioanalytical strategies are evolving in response to this complexity. The panel will consider how CMC, PK, and bioanalytical evidence can be connected to support informed decisions from molecular design and early development through manufacturing.

What You’ll Learn:

• Explore how next-generation bioconjugate formats are changing analytical and bioanalytical requirements
• Gain insights into evaluating critical quality attributes, heterogeneity, stability, and clinically relevant species
• Understand how CMC, PK, and bioanalytical evidence can inform development and manufacturing decisions
• Hear expert perspectives on the capabilities needed to support future bioconjugate modalities

Panelists include:
-Dr. Jim Shen, Executive Director, Bioanalysis and Translational Mass Spectrometry, Bristol Myers Squibb
-Dr. Fabio Rossi, Dir. of Analytical Development, Abzena
-Niomi Peckham, Director, Pipeline Development, United States Pharmacopeia

This is a free 60-minute webinar. If you attend the live event, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Click Here to Register